Fecal shedding of SARS-CoV-2 in infants born to SARS-CoV-2 positive mothers: a pilot study

PeerJ. 2024 Aug 27:12:e17956. doi: 10.7717/peerj.17956. eCollection 2024.

Abstract

Background: Fecal shedding of SARS-CoV-2 occurs during infection, particularly in pediatric populations. The gut microbiota are associated with resistance to enteric pathogens. COVID-19 is associated with alterations to the gut microbiome. We hypothesized that the gut microbiome of infants born to SARS-CoV-2+ mothers differs between infants with and without fecal shedding of the virus.

Methods: We enrolled 10 infants born to SARS-CoV-2+ mothers. We used qPCR on fecal RNA to test for SARS-CoV-2 and 16S rRNA gene sequencing of the V4 region to assess the gut microbiome. Infant SARS-CoV-2 status from nasal swabs was abstracted from medical records.

Results: Of the 10 included infants, nine were tested for SARS-CoV-2 by nasal swab with 1 testing positive. Four infants, including the nasal swab positive infant, had at least one sample with detectable levels of SARS-CoV-2 fecal shedding. Detection of both SARS-CoV-2 genes in feces was associated with increased gut alpha diversity compared to no detection by a linear mixed effects model (p < 0.001). Detection of both SARS-CoV-2 genes was associated with increased levels Erysipelotrichaceae, Lactobacillaceae, and Ruminococceae by MaAsLin2.

Conclusion: Fecal shedding of SARS-CoV-2 occurs in infants who test negative on nasal swabs and is associated with differences in the gut microbiome.

Keywords: Fecal shedding; Infant gut microbiome; SARS-CoV-2.

MeSH terms

  • Adult
  • COVID-19* / diagnosis
  • COVID-19* / transmission
  • COVID-19* / virology
  • Feces* / microbiology
  • Feces* / virology
  • Female
  • Gastrointestinal Microbiome* / genetics
  • Humans
  • Infant
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical
  • Male
  • Mothers
  • Pilot Projects
  • Pregnancy
  • Pregnancy Complications, Infectious / microbiology
  • Pregnancy Complications, Infectious / virology
  • RNA, Ribosomal, 16S / genetics
  • SARS-CoV-2* / genetics
  • SARS-CoV-2* / isolation & purification
  • Virus Shedding*

Substances

  • RNA, Ribosomal, 16S

Grants and funding

This project was funded by a UC Davis COVID19 Research Accelerator Funding Track (CRAFT) grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.